O6-benzylguanine Followed by Surgery in Treating Patients With Solid Tumors That Can Be Removed During Surgery
Determination of Optimal O6-Benzylguanine Dose to Achieve O6-Alkylguanine-DNA Alkyltransferase Depletion in Patients With Surgically Resectable Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving a chemotherapy drug before surgery may shrink the tumor so that it can be removed during surgery.
PURPOSE: Phase II trial to study the effectiveness of O6-benzylguanine followed by surgery in treating patients who have solid tumors that can be removed during surgery.
研究概览
详细说明
OBJECTIVES: I. Determine the minimal O6-benzylguanine (O6-BG) dose required to deplete tumor activity to less than 10 fmol/mg protein at a specified time after administration in patients with surgically resectable solid tumors. II. Correlate tumor tissue AGT depletion with AGT depletion in peripheral blood mononuclear cells (PBMC) obtained at a specified time after O6-BG administration in these patients.
OUTLINE: This is a dose escalation study. Patients receive a single dose of O6-benzylguanine (O6-BG) IV over 1 hour at one of two dose levels. Patients undergo surgery 16-20 hours after administration of O6-BG. Up to 13 patients receive the lower dose level of O6-BG. If more than 3 patients have detectable AGT levels, additional patients receive the higher dose. The optimal biologic dose (OBD) is defined as the lowest dose level at which at least 11 of 13 patients have AGT activity less than 10 fmol/mg protein after O6-BG dosing. Patients are followed at 1 and 3 weeks post surgery.
PROJECTED ACCRUAL: A total of 13-26 patients will be accrued for this study over approximately 10 months.
研究类型
注册 (实际的)
阶段
- 阶段1
联系人和位置
学习地点
-
-
Illinois
-
Chicago、Illinois、美国、60637-1470
- University of Chicago Cancer Research Center
-
-
参与标准
资格标准
适合学习的年龄
- 孩子
- 成人
- 年长者
接受健康志愿者
有资格学习的性别
描述
DISEASE CHARACTERISTICS: Histologically or cytologically confirmed surgically resectable solid tumor
PATIENT CHARACTERISTICS: Age: Not specified Performance status: CALGB 0-2 Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Bilirubin no greater than 1.5 times upper limit of normal (ULN) Renal: Creatinine no greater than 1.5 times ULN Other: Not pregnant or nursing Medically cleared for surgery No active medical or psychiatric disease that would prevent compliance
PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior chemotherapy Endocrine therapy: Not specified Radiotherapy: No prior radiotherapy Surgery: Not specified
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
---|---|
实验性的:Arm A
06-benzylguanine (100mg/m2 16 hrs before anticipated tumor tissue removal)
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Determine minimal dose
大体时间:2 years
|
Determine minimal dose of 06-benzylguanine (06-BG) at which there is a depletion of tumor 06-BG DNA alkyltransferase activity to <10 fmol/mg protein
|
2 years
|
合作者和调查者
调查人员
- 学习椅:Mark J. Ratain, MD、University of Chicago
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
关键字
其他相关的 MeSH 术语
其他研究编号
- 9523
- UCCRC-9523
- NCI-T98-0038
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.
O6-苄基鸟嘌呤的临床试验
-
Duke UniversityNational Institutes of Health (NIH); Keryx / AOI Pharmaceuticals, Inc.完全的
-
Duke UniversitySchering-Plough; Keryx / AOI Pharmaceuticals, Inc.完全的
-
Southwest Oncology GroupNational Cancer Institute (NCI)完全的
-
Duke UniversityPharmacia; Keryx / AOI Pharmaceuticals, Inc.完全的
-
Sidney Kimmel Comprehensive Cancer Center at Johns...National Cancer Institute (NCI)完全的
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)完全的
-
National Cancer Institute (NCI)完全的肉瘤 | 肾癌 | 未明确的儿童实体瘤,具体方案 | 卵巢癌 | 脑和中枢神经系统肿瘤 | 成神经细胞瘤 | 肝癌 | 性腺外生殖细胞瘤 | 儿童生殖细胞肿瘤美国